1. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018; 392:593–606. PMID:
30078459.
2. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374:2209–2221. PMID:
27276561.
3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116:354–365. PMID:
20385793.
4. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481:506–510. PMID:
22237025.
5. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016; 6:e441. PMID:
27367478.
6. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129:424–447. PMID:
27895058.
8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107:3481–3485. PMID:
16455952.
9. Shah A, Andersson TM, Rachet B, Björkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population based study. Br J Haematol. 2013; 162:509–516. PMID:
23786647.
10. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006; 107:2099–2107. PMID:
17019734.
11. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60:454–462. PMID:
6953986.
12. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016; 127:71–78. PMID:
26660428.
13. Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol. 2012; 6:205–217. PMID:
22654526.
14. Raj RV, Abedin SM, Atallah E. Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res. 2018; 74:113–120. PMID:
30401522.
17. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009; 114:937–951. PMID:
19357394.
18. Vardiman JW. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact. 2010; 184:16–20. PMID:
19857474.
19. Leone G, Fianchi L, Pagano L, Voso MT. Incidence and susceptibility to therapy-related myeloid neoplasms. Chem Biol Interact. 2010; 184:39–45. PMID:
20026017.
20. Porwit A. Role of flow cytometry in diagnostics of myelodysplastic syndromes-beyond the WHO 2008 classification. Semin Diagn Pathol. 2011; 28:273–282. PMID:
22195405.
21. Vardiman J. The classification of MDS: From FAB to WHO and beyond. Leuk Res. 2012; 36:1453–1458. PMID:
22940257.
23. National Center for Health Statistics. Estimates of funding for various research, condition, and disease categories (RCDC). Bethesda, MD: National Institutes of Health;2019. Accessed October 3, 2019. at
https://report.nih.gov/categorical_spending.aspx.
25. Ibrahim JK, Sorensen AA, Grunwald H, Burris S. Supporting a culture of evidence-based policy: federal funding for public health law evaluation research, 1985-2014. J Public Health Manag Pract. 2017; 23:658–666. PMID:
28538338.
27. Ball P. Index aims for fair ranking of scientists. Nature. 2005; 436:900. PMID:
16107806.
28. Hirsch JE. An index to quantify an individual's scientific research output. Proc Natl Acad Sci U S A. 2005; 102:16569–16572. PMID:
16275915.
29. Bradford SC. Sources of information on specific subjects. Journal of Information Science. 1985; 10:173–175.
30. Brookes BC. Bradford's law and the bibliography of science. Nature. 1969; 224:953–956. PMID:
4902657.